Faron Pharmaceuticals Ltd: Director Dealing

July 2, 2025 6:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Tuomo Pätsi, Non-Executive Chairman of the Company, acquired 21,500 ordinary shares in Faron at price of €2.435 per share on 30 June 2025. Following this purchase, Mr. Pätsi directly holds 53,265 ordinary shares in the Company, representing 0.05 per cent. of the voting rights...

Read more

Imagene AI Hits $45M in Total Funding After Completing $23M Series B Led by Larry Ellison

July 1, 2025 8:00 AM

Imagene AI, a pioneer in multi‑modal foundation models for precision medicine, today announced the successful close of a $23 million Series B financing round led by Oracle Chairman and CTO Larry Ellison. This latest infusion brings Imagene AI's total capital raised to $45 million under terms that reflect the company's accelerating momentum and expanding strategic footprint. The round also included participation from existing investor Aguras...

Read more

180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets

July 1, 2025 7:30 AM

180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector, today announced two significant value enhancements to its existing, legacy intellectual property ("IP") portfolio-reinforcing part of the Company's strategy relating to continuing to build shareholder value through scientific innovation and patent protection for legacy IP assets. These new...

Read more

Alligator to Present 24-Month OPTIMIZE-1 Data at ESMO GI 2025

July 1, 2025 3:00 AM

Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that new data from the ongoing OPTIMIZE-1 study, evaluating the CD40 agonist mitazalimab in combination with mFOLFIRINOX in metastatic pancreatic cancer, will be presented at the ESMO Gastrointestinal Cancers Congress 2025, taking place in Barcelona on 2-5 July.The poster includes 24-month efficacy...

Read more

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

June 30, 2025 9:21 AM

Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integrated into Renovaro's Defense Countermeasures Program, marking a strategic entry into the dual-use biotechnology and biodefense sector. Renovaro's platform is...

Read more

Change in Number of Shares and Votes in Alligator Bioscience AB

June 30, 2025 9:15 AM

During June 2025, the number of shares and votes in Alligator Bioscience AB (STO:ATORX) ("Alligator Bioscience")has increased as a result of the exercise of warrants series TO 12, issued in connection with the rights issue of units carried out during December 2024 - February 2025 (the "Warrant Programme"), as well as the directed new share issues of ordinary shares to guarantors in the Warrant Programme, which were resolved by the Board of...

Read more

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

June 30, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today unveiled the key achievements and advancements that defined Fiscal Year 2025, ended March 31, 2025. This past year has been nothing short of transformative, marked by significant clinical progress, strategic expansion, and growing recognition for our...

Read more

Faron Pharmaceuticals Ltd: Director/PCA Dealing

June 30, 2025 7:15 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Dr Juho Jalkanen, Chief Executive Officer of the Company, acquired 22,127 ordinary shares in Faron at price of €2.26 per share on 27 June 2025. Following this purchase, Dr Jalkanen directly holds 1,112,015 ordinary shares in the Company, representing 0.99 per cent of the voting...

Read more

Increase in Number of Shares and Votes in Vicore Pharma

June 30, 2025 3:20 AM

Vicore Pharma Holding AB (publ) (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the number of Vicore shares and votes has increased following the exercise of warrants with subsequent delivery of shares to a participant in the incentive programs Board LTIP 2023 and Board LTIP 2024. The shares were issued through the exercise of 30,652 share...

Read more

Faron-Supported Research in Theranostics Identifies Secreted Clever-1 (sClever-1) as an Independent Driver of Immune Evasion in Cancer, Deepening the Understanding of Bexmarilimab’s Mode of Action

June 30, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, announced the publication of a new study in the peer-reviewed journal Theranostics . The research identified a secreted, truncated form of the Clever-1 receptor (sClever-1) as a key immunosuppressive mediator in cancer that impaired T-cell responses and was associated with resistance to...

Read more

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

June 27, 2025 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company will host a conference call and webcast on Monday, June 30, 2025, at 11:00 a.m. Eastern Time to review the Company's operational progress for the fiscal year ended March 31, 2025. The Company will release its fiscal year 2025 financial results that day before the market opens.To participate in the call by phone, dial (888) 506 0062 approximately five...

Read more

Biovica International AB - Annual Report for the Financial Year 2024/2025 Published

June 27, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Annual Report for the finacial year 2024/2025 for Biovica International AB is published today on our website.See URL belowContactAnders Rylander, CEOPhone: +46 76 666 16 47E-mail: [email protected] Morén, CFOPhone: +46 73 125 92 46E-mail: [email protected] Rylander, CEO Phone: +46-18-444 48 35E-mail: [email protected] - Treatment...

Read more

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

June 26, 2025 4:10 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its role in the Meta-PURE initiative, a $9.2 million USD National Science Foundation (NSF) funded project under the CFIRE program aimed at transforming the scalability and accessibility of cell-free systems to expand real-world applications.Led by...

Read more

Biovica Granted New European Patent

June 26, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica today announced that the European Patent Office (EPO) has granted a new patent for the company's biomarker technology in the field of immuno-oncology. The patent covers the use of TKa as a marker for predicting the efficacy of immune checkpoint inhibitor (ICI) treatment in cancer patients. The patent will come into effect on July 16, 2025, in conjunction with its publication...

Read more

Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position

June 25, 2025 9:15 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces the strategic deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals LLC ("Metuchen"), including its wholly owned subsidiaries, Timm Medical Technologies, Inc. and Pos-T-Vac, LLC, from its consolidated balance sheet,...

Read more

Pulpfixin Partners With University of Dayton Research Institute to Validate Performance and Sustainability of Pulp-based Labware

June 24, 2025 11:00 PM

PulpFixin, a leader in sustainable product solutions for the scientific community, today announced a strategic collaboration with the University of Dayton Research Institute (UDRI) to scientifically validate the performance, durability, and material properties of its biodegradable and recyclable AutoRacks, Cryogenic Boxes, Pipet Tip boxes, AutoBoxes and other structural replacements of plastics throughout the Sciences. As part of this...

Read more

Multi-Institutional Team Awarded NCI Grant to Open Novel AML Trial

June 23, 2025 10:10 AM

The University of Cincinnati Cancer Center (UC), The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and Jabez Biosciences are partnering to open a new phase 1 clinical trial studying JBZ-001, a potential new treatment for acute myeloid leukemia (AML).The trial is supported by a more than $3.4 million grant from the National Institutes of Health's...

Read more

ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology

June 23, 2025 9:00 AM

ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows.As H5N1 outbreaks continue to...

Read more

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

June 23, 2025 8:30 AM

IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Oklahoma, for its Phase 2 CALMA study evaluating IGC-AD1 for agitation in Alzheimer's dementia. This expansion into the Oklahoma City metropolitan area underscores IGC's commitment to diversifying its trial population and addressing regional healthcare disparities.Tekton Research has extensive...

Read more

Elizabeth Fraley, CEO of Kinder Ready Offers a Comprehensive Guide to Navigating the Private School Application Process.

June 21, 2025 4:00 PM

Navigating the private school application process can be a complex and overwhelming experience for parents. From researching schools and completing applications to preparing for interviews, the journey requires careful planning and insight. To support families in making informed decisions, Elizabeth Fraley Kinder Ready provides a step-by-step guide to simplify the process.Elizabeth Fraley Kinder Ready has established itself as a leader that...

Read more